Traders should monitor upcoming earnings disclosures and any changes in revenue or cash flow trends, as significant C-suite selling may signal lack of confidence in near-term prospects despite ongoing equity grants.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 9 $23.30entry
- T+1 · 8mo ago −3.56%α −3.38% · $22.47
- T+5 · 8mo ago −5.75%α −4.40% · $21.96
- T+20 · 7mo ago −3.95%α −1.14% · $22.38
- T+60 · 6mo ago −10.73%α −22.72% · $20.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Privia Health executives, including CEO Parth Mehrotra and CFO David Mountcastle, conducted open-market share sales totaling $1.95M over three days in mid-March 2026, concurrent with routine stock award grants. The sales represent a coordinated insider selling event by top leadership.
Key Financial Metrics
Key Facts
- CEO Parth Mehrotra sold 75,089 shares for $1.65M across three transactions (March 10–13).
- CFO David Mountcastle sold 13,018 shares for $282,600 over two days (March 12–13).
- Total open-market sales by insiders: $1.95M in 7 days.
- Sales represent approximately 0.07% of PRVA's $2.7B market cap, modest but meaningful for insider activity.
- Concurrent with sales, executives received non-cash stock awards totaling $0 value (routine compensation).
Financial Impact
$1.95 million in open-market insider selling by C-suite executives
Risk Factors
- Insider selling may indicate belief that stock is overvalued or anticipation of weaker-than-expected results.
- Concentration of selling among CEO and CFO increases signal strength compared to lower-level insider trades.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (10 trades, 7d window) | cluster-PRVA-1773692225642 |
Track record
20 reports on PRVA
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.73% at T+60 after the Mar 9, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Mixed 6/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $23.94 to $23.67 Now $25.26 −5.51% ▲ +1.13% +4.42% vs SPY
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $21.28 to $24.54 Now $25.26 +18.70% ▲ +15.32% +15.24% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $21.48 to $24.42 Now $25.26 +17.60% ▲ +13.69% +16.39% vs SPY
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $20.30 to $21.67 Now $25.26 +24.43% ▲ +6.75% +7.73% vs SPY
- Jul 13, 202618w ago Insider Cluster Neutral 3/10 Entry $28.03 to $26.26 Now $25.26 −9.88% ▼ −6.31% −5.02% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 3/10 Entry $27.49 to $26.90 Now $25.26 −8.11% ▼ −2.15% −0.60% vs SPY
- Jul 7, 202618w ago Insider Cluster Neutral 3/10 Entry $27.21 to $28.10 Now $25.26 −7.17% ▲ +3.27% +2.01% vs SPY
- Jul 7, 202618w ago Press Release Neutral 1/10 Entry $27.23 to $28.03 Now $25.26 −7.23% ▲ +2.94% +2.39% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 3/10 Entry $27.36 to $27.77 Now $25.26 −7.68% ▲ +1.50% +0.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers